"This is one of the first tests of a proteomic profile in a prospective-blind fashion," said Catalin S. Buhimschi, M.D., assistant professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale University. "One of the key advances in this research is that the test was done using fresh samples of amniotic fluid and not using banked amniotic fluid. This is a multidisciplinary approach that combines the basic science with clinical neonatology."
Mass Restricted (MR) score is a specific proteomic profile used in the study. Presence of the biomarkers indicating inflammation in amniotic fluid can be established in 20 to 30 minutes. This test is much faster than the current method of testing microbiological cultures. If no biomarkers are present, then the pregnancy is uncomplicated.
Buhimschi and his team studied 164 fresh samples of amniotic fluid from 131 patients recruited consecutively with symptoms of premature labor. Proteins in a small sample of amniotic fluid were tested to find a link between the amniotic fluid glucose value, white blood cell count and the outcome of the fetus. An MR sore of three or four is highly predictive of adverse pregnancy outcome.
"We can now detect infections at a much more incipient stage with this proteomic profile," said Buhimschi. "The presence of two biomarkers for inflammation indicates the median time for delivery is four days. If all the biomarkers for inflammation are present, delivery time occurs within hours. Studies to test treatment were not possible before. We now have to take it into the clinic and use the results of this test to provide a rapid treatment to the mother and its baby. This platform is also available to help diagnose other diseases."
MEDICA.de; Source: Yale University